In pharmaceutical and biochemical contexts, solubility is one of the foundational properties determining how a compound behaves in biological systems. A substance classified as "freely soluble" will disperse readily in an aqueous medium, whilst one described as "practically insoluble" will form only negligible concentrations even under ideal conditions. The British and Australian conventions follow the definitions codified in pharmacopoeial standards , the British Pharmacopoeia and the United States Pharmacopeia both provide standardised descriptive terms (sparingly soluble, slightly soluble, very slightly soluble, and so on) with precise concentration ranges attached to each.
Solubility is distinct from the rate of dissolution (how quickly a solute dissolves) and from stability in solution (how long it remains dissolved without degrading or precipitating). All three properties matter in formulation science, but solubility sets the theoretical ceiling that the other two operate within.
For plant-derived compounds and cannabinoids specifically, aqueous solubility is frequently low because many of these molecules are highly lipophilic , they partition preferentially into oils and fats rather than water. This has direct consequences for bioavailability and for the formulation strategies used to deliver them, including emulsification, nanoemulsion, and cyclodextrin complexation. The Therapeutic Goods Administration (TGA) requires that solubility data be supplied as part of the chemistry, manufacturing and controls (CMC) documentation for any registered medicine or listed product.
Solubility can be measured experimentally via equilibrium solubility assays or kinetic (nephelometric) assays, and predicted computationally using physicochemical descriptors such as logP (the octanol-water partition coefficient) and polar surface area. Neither method is infallible; experimental and predicted values can diverge substantially for complex natural product molecules.
Sources: